Investigational Drug Details
| Drug ID: | D377 |
| Drug Name: | TRO19622 |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB05185 |
| DrugBank Description: | TRO19622 is a cholesterol-like small molecule that has demonstrated a remarkable neuroprotective profile in a battery of both in vitro and in vivo preclinical models. For example, it has demonstrated the ability to prevent neurodegeneration, enhance nerve function and accelerate neuroregeneration following nerve trauma. |
| PubChem ID: | 9930827 |
| CasNo: | 66538-08-7 |
| Repositioning for NAFLD: | No |
| SMILES: | C[C@]12[C@H]([C@H]3[C@H](CC2)[C@]2(C)C(=C/C(=N/O)/CC2)CC3)CC[C@@H]1[C@@H](CCCC(C)C)C |
| Structure: |
|
| InChiKey: | QNTASHOAVRSLMD-SIWSWZRQSA-N |
| Molecular Weight: | 399.663 |
| DrugBank Targets: | -- |
| DrugBank MoA: | TRO19622 interacts with a physiologically relevant target: the mitochondrial permeability transition pore (mPTP). Mitochondria are central mediators of cell death and are implicated in most if not all neurodegenerative diseases regardless of the initiating factor: genetic mutations, excitotoxicity, reactive oxygen species, ischemia, chemical toxicity, etc. Mitochondria play diverse roles in all cells. In neurons, especially near synaptic sites, mitochondria are essential calcium-buffering organelles in areas where membrane excitability leads to large influx of calcium through calcium channels. Mitochondria also produce the ATP necessary for microtubule-based axoplasmic transport and maintaining the activity of ion and nutrient transporters. If a neuron fails to establish or maintain its functional role, mitochondria are responsible for eliminating it by releasing apoptotic factors. TRO19622, by interacting with protein components of the mPTP, prevents the release of these apoptotic factors and therefore protects the neuron. This mechanism of action may lead to a general neuroprotective activity with utility in other therapeutic indications. |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | Investigated for use/treatment in neurologic disorders. |
| Targets: | mPTP |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 completed (NCT00666016) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0180 | NCT00666016 | Phase 2 | Completed | No Results Available | April 2008 | November 22, 2016 | Details |
| L0695 | EUCTR2007-005089-12-FR | Not applicable | Authorised | No Results Available | 04/10/2007 | 19 March 2012 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|